SidaSubSaharaV1, PubMed, Checkpoint, bibRecord, 000B91

Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.

Identifieur interne : 000B91 ( PubMed/Checkpoint ); précédent : 000B90; suivant : 000B92

Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.

Auteurs : Tanuja N. Gengiah [Afrique du Sud] ; Atika Moosa ; Anushka Naidoo ; Leila E. Mansoor

Source :

International journal of clinical pharmacy [ 2210-7711 ] ; 2014.

RBID : pubmed:24129582

Descripteurs français

KwdFr :
- Administration par voie orale, Administration par voie topique, Agents antiVIH (administration et posologie), Agents antiVIH (pharmacologie), Agents antiVIH (usage thérapeutique), Humains, Infections à VIH (), Infections à VIH (psychologie), Infections à VIH (traitement médicamenteux), Observance du traitement médicamenteux (psychologie).
MESH :
- administration et posologie : Agents antiVIH.
- pharmacologie : Agents antiVIH.
- psychologie : Infections à VIH, Observance du traitement médicamenteux.
- traitement médicamenteux : Infections à VIH.
- usage thérapeutique : Agents antiVIH.
- Administration par voie orale, Administration par voie topique, Humains, Infections à VIH.

English descriptors

KwdEn :
- Administration, Oral, Administration, Topical, Anti-HIV Agents (administration & dosage), Anti-HIV Agents (pharmacology), Anti-HIV Agents (therapeutic use), HIV Infections (drug therapy), HIV Infections (prevention & control), HIV Infections (psychology), Humans, Medication Adherence (psychology).
MESH :
- chemical , administration & dosage : Anti-HIV Agents.
- chemical , pharmacology : Anti-HIV Agents.
- chemical , therapeutic use : Anti-HIV Agents.
- drug therapy : HIV Infections.
- prevention & control : HIV Infections.
- psychology : HIV Infections, Medication Adherence.
- Administration, Oral, Administration, Topical, Humans.

Abstract

There are 34 million people living with human immunodeficiency virus (HIV) worldwide and each year this number increases. Until a vaccine is discovered, the prevention of new HIV infections remains an urgent priority. Several trials studying the use of oral and topical agents for the prevention of HIV infection have already been completed. Adherence has proved to be a major challenge in achieving product efficacy.

DOI: 10.1007/s11096-013-9861-1
PubMed: 24129582

Affiliations:

Afrique du Sud

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001647
to stream PubMed, to step Curation: 001647

Links to Exploration step

pubmed:24129582

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.</title>
<author><name sortKey="Gengiah, Tanuja N" sort="Gengiah, Tanuja N" uniqKey="Gengiah T" first="Tanuja N" last="Gengiah">Tanuja N. Gengiah</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), 2nd Floor, K-RITH Tower Building, University of KwaZulu-Natal, 719 Umbilo Road, Durban, 4001, South Africa, gengiaht1@ukzn.ac.za.</nlm:affiliation>
<country wicri:rule="url">Afrique du Sud</country>
<wicri:regionArea>Centre for the AIDS Programme of Research in South Africa (CAPRISA), 2nd Floor, K-RITH Tower Building, University of KwaZulu-Natal, 719 Umbilo Road, Durban, 4001, South Africa</wicri:regionArea>
<wicri:noRegion>South Africa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moosa, Atika" sort="Moosa, Atika" uniqKey="Moosa A" first="Atika" last="Moosa">Atika Moosa</name>
</author>
<author><name sortKey="Naidoo, Anushka" sort="Naidoo, Anushka" uniqKey="Naidoo A" first="Anushka" last="Naidoo">Anushka Naidoo</name>
</author>
<author><name sortKey="Mansoor, Leila E" sort="Mansoor, Leila E" uniqKey="Mansoor L" first="Leila E" last="Mansoor">Leila E. Mansoor</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24129582</idno>
<idno type="pmid">24129582</idno>
<idno type="doi">10.1007/s11096-013-9861-1</idno>
<idno type="wicri:Area/PubMed/Corpus">001647</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001647</idno>
<idno type="wicri:Area/PubMed/Curation">001647</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001647</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001647</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001647</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.</title>
<author><name sortKey="Gengiah, Tanuja N" sort="Gengiah, Tanuja N" uniqKey="Gengiah T" first="Tanuja N" last="Gengiah">Tanuja N. Gengiah</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), 2nd Floor, K-RITH Tower Building, University of KwaZulu-Natal, 719 Umbilo Road, Durban, 4001, South Africa, gengiaht1@ukzn.ac.za.</nlm:affiliation>
<country wicri:rule="url">Afrique du Sud</country>
<wicri:regionArea>Centre for the AIDS Programme of Research in South Africa (CAPRISA), 2nd Floor, K-RITH Tower Building, University of KwaZulu-Natal, 719 Umbilo Road, Durban, 4001, South Africa</wicri:regionArea>
<wicri:noRegion>South Africa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moosa, Atika" sort="Moosa, Atika" uniqKey="Moosa A" first="Atika" last="Moosa">Atika Moosa</name>
</author>
<author><name sortKey="Naidoo, Anushka" sort="Naidoo, Anushka" uniqKey="Naidoo A" first="Anushka" last="Naidoo">Anushka Naidoo</name>
</author>
<author><name sortKey="Mansoor, Leila E" sort="Mansoor, Leila E" uniqKey="Mansoor L" first="Leila E" last="Mansoor">Leila E. Mansoor</name>
</author>
</analytic>
<series><title level="j">International journal of clinical pharmacy</title>
<idno type="eISSN">2210-7711</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Administration, Topical</term>
<term>Anti-HIV Agents (administration & dosage)</term>
<term>Anti-HIV Agents (pharmacology)</term>
<term>Anti-HIV Agents (therapeutic use)</term>
<term>HIV Infections (drug therapy)</term>
<term>HIV Infections (prevention & control)</term>
<term>HIV Infections (psychology)</term>
<term>Humans</term>
<term>Medication Adherence (psychology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale</term>
<term>Administration par voie topique</term>
<term>Agents antiVIH (administration et posologie)</term>
<term>Agents antiVIH (pharmacologie)</term>
<term>Agents antiVIH (usage thérapeutique)</term>
<term>Humains</term>
<term>Infections à VIH ()</term>
<term>Infections à VIH (psychologie)</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Observance du traitement médicamenteux (psychologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiVIH</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Infections à VIH</term>
<term>Observance du traitement médicamenteux</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>HIV Infections</term>
<term>Medication Adherence</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Administration, Topical</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term>
<term>Administration par voie topique</term>
<term>Humains</term>
<term>Infections à VIH</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There are 34 million people living with human immunodeficiency virus (HIV) worldwide and each year this number increases. Until a vaccine is discovered, the prevention of new HIV infections remains an urgent priority. Several trials studying the use of oral and topical agents for the prevention of HIV infection have already been completed. Adherence has proved to be a major challenge in achieving product efficacy.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24129582</PMID>
<DateCreated><Year>2014</Year>
<Month>01</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted><Year>2014</Year>
<Month>12</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2210-7711</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>36</Volume>
<Issue>1</Issue>
<PubDate><Year>2014</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>International journal of clinical pharmacy</Title>
<ISOAbbreviation>Int J Clin Pharm</ISOAbbreviation>
</Journal>
<ArticleTitle>Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.</ArticleTitle>
<Pagination><MedlinePgn>70-85</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11096-013-9861-1</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There are 34 million people living with human immunodeficiency virus (HIV) worldwide and each year this number increases. Until a vaccine is discovered, the prevention of new HIV infections remains an urgent priority. Several trials studying the use of oral and topical agents for the prevention of HIV infection have already been completed. Adherence has proved to be a major challenge in achieving product efficacy.</AbstractText>
<AbstractText Label="AIM OF THE REVIEW" NlmCategory="OBJECTIVE">To provide the clinical pharmacist with an understanding of the oral pre-exposure prophylaxis (PrEP) and topical microbicide product pipeline whilst emphasizing the critical importance of adherence to these drugs to avert HIV infection.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">PubMed/Medline and the web-based clinical trials registry (ClinTrials.gov) were searched using appropriate key words. For the time period 1992-2013--all phase II and phase III safety and effectiveness studies--testing agents for prevention of HIV infection were included in the review. Efficacy estimates, adherence estimates and reported challenges with adherence were extracted.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-four phase II and III clinical trials were found during review. Of these, 20 trials have been completed, and six trials show effectiveness in preventing HIV infection. The majority of the successful trials were to oral PrEP and to date only one microbicide trial of a vaginal antiretroviral microbicide gel has showed effectiveness. Adherence to study product played a major role in trial outcomes and there are several reasons for non-adherence. These include high on-trial pregnancy rates, low trial retention rates, low participant perception of risk, participant characteristics such as age <25 years, single status, migratory partners and trial fatigue. Study product characteristics such as dosage form, dosing interval, as well as associated adverse events may also influence adherence.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Moderate to high adherence is critical to demonstrate efficacy of drugs for HIV prevention. For topical agents, intermittent use associated with coitus is more effective than daily use, particularly if sex is infrequent or partners migrant. For oral agents, daily use is effective but the motivation to use the drug and high risk perception is important. In serodiscordant couples, early initiation of highly active antiretroviral therapy in the infected partner affords almost complete protection to the negative partner. Drugs need to be tailored to the population at risk and availability of multiple drug options are important.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gengiah</LastName>
<ForeName>Tanuja N</ForeName>
<Initials>TN</Initials>
<AffiliationInfo><Affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), 2nd Floor, K-RITH Tower Building, University of KwaZulu-Natal, 719 Umbilo Road, Durban, 4001, South Africa, gengiaht1@ukzn.ac.za.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moosa</LastName>
<ForeName>Atika</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Naidoo</LastName>
<ForeName>Anushka</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mansoor</LastName>
<ForeName>Leila E</ForeName>
<Initials>LE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>D43 TW000231</GrantID>
<Acronym>TW</Acronym>
<Agency>FIC NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U19 AI051794</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI51794</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>D43TW00231</GrantID>
<Acronym>TW</Acronym>
<Agency>FIC NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>10</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Int J Clin Pharm</MedlineTA>
<NlmUniqueID>101554912</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):207-10</RefSource>
<PMID Version="1">21654503</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS Care. 2013 Aug;25(8):961-7</RefSource>
<PMID Version="1">23252473</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2011 Jul 16;378(9787):279-81</RefSource>
<PMID Version="1">21763939</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 1992 Jul 22-29;268(4):477-82</RefSource>
<PMID Version="1">1320133</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Oct 16;376(9749):1329-37</RefSource>
<PMID Version="1">20851460</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2002 Sep 28;360(9338):971-7</RefSource>
<PMID Version="1">12383665</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sex Transm Infect. 2010 Jun;86(3):222-6</RefSource>
<PMID Version="1">20444744</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 2;367(5):423-34</RefSource>
<PMID Version="1">22784038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 2;367(5):399-410</RefSource>
<PMID Version="1">22784037</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 2010 Sep 3;329(5996):1168-74</RefSource>
<PMID Version="1">20643915</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sci Transl Med. 2012 Sep 12;4(151):151ra125</RefSource>
<PMID Version="1">22972843</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 2;367(5):411-22</RefSource>
<PMID Version="1">22784040</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2008 Dec 6;372(9654):1977-87</RefSource>
<PMID Version="1">19059048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2011 Apr 24;25(7):957-66</RefSource>
<PMID Version="1">21330907</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2007;2(12):e1312</RefSource>
<PMID Version="1">18091987</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Soc Sci Med. 2012 Nov;75(9):1555-61</RefSource>
<PMID Version="1">22495513</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Dec;22 Suppl 4:S17-25</RefSource>
<PMID Version="1">19033752</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Jul 31;359(5):463-72</RefSource>
<PMID Version="1">18669425</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2013 Jun 15;381(9883):2083-90</RefSource>
<PMID Version="1">23769234</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2012 Nov;28(11):1412-21</RefSource>
<PMID Version="1">22943559</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2011 Jan;27(1):81-90</RefSource>
<PMID Version="1">20969483</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sex Transm Dis. 2001 Jul;28(7):394-400</RefSource>
<PMID Version="1">11460023</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1998 Aug 20;339(8):504-10</RefSource>
<PMID Version="1">9709043</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(1):e55013</RefSource>
<PMID Version="1">23383037</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):463-8</RefSource>
<PMID Version="1">22267018</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trials. 2014 Dec 19;15:496</RefSource>
<PMID Version="1">25527071</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Aug 11;365(6):493-505</RefSource>
<PMID Version="1">21767103</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Dec 30;363(27):2587-99</RefSource>
<PMID Version="1">21091279</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Int AIDS Soc. 2013;16:18505</RefSource>
<PMID Version="1">23561044</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS Behav. 2013 Jul;17(6):2143-55</RefSource>
<PMID Version="1">23435697</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):490-8</RefSource>
<PMID Version="1">22932322</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2012 Apr 24;26(7):F13-9</RefSource>
<PMID Version="1">22333749</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS Care. 2010 Aug;22(8):997-1005</RefSource>
<PMID Version="1">20552466</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS Behav. 2013 Feb;17(2):737-47</RefSource>
<PMID Version="1">23065145</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2012;7(4):e33103</RefSource>
<PMID Version="1">22511916</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2008;3(11):e3784</RefSource>
<PMID Version="1">19023429</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2008;3(1):e1474</RefSource>
<PMID Version="1">18213382</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000287" MajorTopicYN="N">Administration, Topical</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName>
<QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS532132</OtherID>
<OtherID Source="NLM">PMC3947256</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>05</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>09</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>10</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>10</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>12</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24129582</ArticleId>
<ArticleId IdType="doi">10.1007/s11096-013-9861-1</ArticleId>
<ArticleId IdType="pmc">PMC3947256</ArticleId>
<ArticleId IdType="mid">NIHMS532132</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Afrique du Sud</li>
</country>
</list>
<tree><noCountry><name sortKey="Mansoor, Leila E" sort="Mansoor, Leila E" uniqKey="Mansoor L" first="Leila E" last="Mansoor">Leila E. Mansoor</name>
<name sortKey="Moosa, Atika" sort="Moosa, Atika" uniqKey="Moosa A" first="Atika" last="Moosa">Atika Moosa</name>
<name sortKey="Naidoo, Anushka" sort="Naidoo, Anushka" uniqKey="Naidoo A" first="Anushka" last="Naidoo">Anushka Naidoo</name>
</noCountry>
<country name="Afrique du Sud"><noRegion><name sortKey="Gengiah, Tanuja N" sort="Gengiah, Tanuja N" uniqKey="Gengiah T" first="Tanuja N" last="Gengiah">Tanuja N. Gengiah</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B91 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000B91 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaSubSaharaV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:24129582
   |texte=   Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:24129582" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SidaSubSaharaV1

This area was generated with Dilib version V0.6.32.
Data generation: Mon Nov 13 19:31:10 2017. Site generation: Wed Mar 6 19:14:32 2024

	Le SIDA en Afrique subsaharienne (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Le SIDA en Afrique subsaharienne (serveur d'exploration)

Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.

Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki